About us

What we can do, for you

DesignMedix, Inc. has a unique, rapid approach for developing drugs to overcome drug resistance. This platform approach is a way of making novel compounds by covalently linking a chemical moiety derived from a resistance reversal agent to a drug that has had strong resistance evolve against it, thereby creating a new drug that can fulfill both roles - drug and resistance reversal. This approach enables the design and synthesis of novel drugs very rapidly to enter the optimization stage of development far sooner than widely-used screening approaches. Development risk is reduced because the approach leverages the safety and efficacy properties of the original drug. 

© Copyright 2014-2015 DesignMedix, Inc.
Call for a quote today! (415) 555-5555
DesignMedix Web Banner
Targeting drug-resistant diseases with dual-action drugs

Novel patentable drugs are created with the ability to reverse drug-resistance. The molecules created may have dual or multiple actions that confer efficacy by a known mode of action as well as reversal of drug resistance. The mechanism of drug resistance has been demonstrated for the anti-malarial drugs.

Peyton, DH: Reversed chloroquine molecules as a strategy to overcome resistance in malaria. Curr. Top. Med. Chem. 2012, 12(5): 400-7.

Burgess, SJ; Kelly, JX; Shomloo, S; Wittlin, S; Brun, R; Liebmann, K; Peyton, DH: Synthesis, Structure-Activity Relationship, and Mode-of-Action Studies of Antimalarial Reversed Chloroquine Compounds. J. Med. Chem. 2010, 53(17): 6477-6489.

Andrews S, Burgess SJ, Skaalrud D, Kelly JX, Peyton DH: Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum. J. Med. Chem. 2010, 53(2):916-919. 

Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH: A Chloroquine-like Molecule Designed to Reverse Resistance in Plasmodium falciparum. J. Med. Chem. 2006, 49(18):5623-5625. 

Kelly, JX, Smilkstein, MJ, Brun, R, Wittlin, S, Cooper, RA, Lane, KD, Janowsky, A, Johnson, RA, Dodean, RA, Winter, R, Hinrichs, DJ, Riscoe, MK: Discovery of dual function acridones as a new antimalarial chemotype. Nature 2009, 459: 270-273. 

Kelly, JX, Smilktein, M, Cooper, RA, Lane, KD, Johnson, RA, Janowsky, A, Dodean, RA, Hinrichs, DJ, Winter, RW, Riscoe, MK: Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother 2007, 51(11), 4133-4140. 

Smilkstein, M, Sriwilaijaroen, N, Kelly JX, Wilairat P, Riscoe, MK: Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 2004, 48,1803-1806.


Strategy synchronising multiple channels

We create a consistent customer experience through a detailed digital strategy built on precise customer research.


Tony Fred, CEO

Founder and chief visionary, Tony is the driving force behind the company. He loves to keep his hands full by participating in the development of the software, marketing, and customer experience strategies.

Mich Stark, COO

Mich loves taking on challenges. With his multi-year experience as Commercial Director in the software industry, Mich has helped the company to get where it is today. Mich is among the best minds.

Aline Turner, CTO

Aline is one of the iconic people in life who can say they love what they do. She mentors 100+ in-house developers and looks after the community of thousands of developers.

Iris Joe, CFO

Iris, with her international experience, helps us easily understand the numbers and improves them. She is determined to drive success and delivers her professional acumen to bring the company to the next level.